Earlier this year, the National Institutes of Health invested $35 million over five years to establish the Antiviral Drug Discovery and Development Center at the University of Alabama at Birmingham. The center, in partnership with the pharmaceutical company Gilead Sciences, will develop drugs for influenza, dengue fever, West Nile virus, SARS, MERS and chikungunya.